Abiopharma

Gaotu Techedu Announces Second Quarter 2026 Unaudited Financial Results

Understood to acquire 50% of the share capital of a company engaged in the field of ground foundation drilling, piles, and concrete pumping services

Tezspire CROSSING trial met primary endpoints

Change in holdings of interested parties/officers

Rule 425- Publication regarding voting deadline

Digital Realty breaks ground on new state-of-the-art data center in Switzerland

AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohns Disease

TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS

The company’s liability position as of 30.6.26, by maturity dates

Q2/half-year report for 2026

Change in holdings of interested parties/officers

General Announcement: Net Asset Value ("NAV") as of 26 August 2026

General Announcement: Request for Lifting of Trading Halt - Sponsors Statement

Request for Lifting of Trading Halt: Request for Lifting of Trading Halt

MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update